Nonalcoholic steatohepatitis (NASH). Nonalcoholic steatohepatitis (NASH)
Conditions
Interventions
Intervention 1: Intervention group: , After obtaining consent, eligible individuals were randomly selected In addition to standard diabetes treatment, they receive the drug empagliflozin at a dose of
Sponsors
Ghoum University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with type 2 diabetes Patients with grade 2 and 3 fatty liver regardless of fibrosis
Exclusion criteria
Exclusion criteria: Patients with liver cirrhosis Patients without fatty liver (hepatitis and drug side effects) Pregnancy and breastfeeding Kidney failure People who have received weight loss medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatty liver grade on fibroscan. Timepoint: Before and 24 weeks after empagliflozin administration. Method of measurement: Fibroscan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index. Timepoint: Before and 24 weeks after empagliflozin administration. Method of measurement: Kg/m2.;Fasting blood sugar. Timepoint: Before and 24 weeks after empagliflozin administration. Method of measurement: Blood sampling.;HbA1C. Timepoint: Before and 24 weeks after empagliflozin administration. Method of measurement: Blood sampling.;Level of liver transaminases. Timepoint: Before and 24 weeks after empagliflozin administration. Method of measurement: Blood sampling. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohamd Abedinifard
Ghoum University of Medical Sciences
Outcome results
None listed